Related references
Note: Only part of the references are listed.Randomized, controlled trial of telcagepant for the acute treatment of migraine
K. M. Connor et al.
NEUROLOGY (2009)
Migraine: an endemic disease inside the blood-brain barrier
Carl Dahlof et al.
FUTURE NEUROLOGY (2009)
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W. Ho et al.
LANCET (2008)
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
T. W. Ho et al.
NEUROLOGY (2008)
Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life
RB Lipton et al.
NEUROLOGY (2005)
The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers
KA Petersen et al.
CEPHALALGIA (2005)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Calcitonin gene-related peptide and its role in migraine pathophysiology
U Arulmani et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
CGRP may play a causative role in migraine
LH Lassen et al.
CEPHALALGIA (2002)
Within-patient consistency of response of rizatriptan for treating migraine
CGH Dahlöf et al.
NEUROLOGY (2000)
Share Paper
